Alnylam Pharmaceuticals, Inc.
🏢 View company profile →433Patents
413Active
433Granted
59Portfolio score
Filing activity: Mar 6, 2003 → Oct 28, 2024 · 102 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8158601B2 | Lipid formulation | Emerging Cross-Sectional Technologies | 293 | Active |
| US8106022B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | Emerging Cross-Sectional Technologies | 229 | Active |
| US7718629B2 | Compositions and methods for inhibiting expression of Eg5 gene | Chemistry; Metallurgy | 211 | Active |
| US7320965B2 | Compositions and methods for inhibiting expression of Huntingtin gene | Chemistry; Metallurgy | 167 | Active |
| US8828956B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | Emerging Cross-Sectional Technologies | 160 | Active |
| US7605251B2 | Compositions and methods for inhibiting expression of the PCSK9 gene | Chemistry; Metallurgy | 149 | Active |
| US7582745B2 | Compositions and methods for inhibiting expression of Nav1.8 gene | Chemistry; Metallurgy | 146 | Active |
| US8450467B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | Emerging Cross-Sectional Technologies | 145 | Active |
| US7723509B2 | IRNA agents with biocleavable tethers | Chemistry; Metallurgy | 118 | Active |
| US7582744B2 | Chemically modified oligonucleotides | Chemistry; Metallurgy | 117 | Expired |
| US7423142B2 | Compositions and methods for inhibiting expression of anti-apoptotic genes | Chemistry; Metallurgy | 115 | Expired |
| US7737265B2 | RNAi modulation of HIF-1 and therapeutic uses thereof | Chemistry; Metallurgy | 111 | Active |
| US7749978B2 | Compositions and methods for inhibiting expression of Huntingtin gene | Chemistry; Metallurgy | 111 | Active |
| US7829693B2 | Compositions and methods for inhibiting expression of a target gene | Chemistry; Metallurgy | 108 | Active |
| US9352048B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | Emerging Cross-Sectional Technologies | 99 | Active |
| US9012498B2 | Biodegradable lipids for the delivery of active agents | Chemistry; Metallurgy | 94 | Active |
| US7786290B2 | Double-stranded ribonucleic acid with increased effectiveness in an organism | Chemistry; Metallurgy | 92 | Active |
| US9290760B2 | Modified iRNA agents | Chemistry; Metallurgy | 90 | Active |
| US9796974B2 | Modified RNAi agents | Chemistry; Metallurgy | 85 | Active |
| US7745608B2 | Modified iRNA agents | Chemistry; Metallurgy | 79 | Expired |
| US8110674B2 | Therapeutic compositions | Chemistry; Metallurgy | 69 | Expired |
| US8344125B2 | Modified iRNA agents | Chemistry; Metallurgy | 51 | Active |
| US8101584B2 | Method and medicament for inhibiting the expression of a given gene | Emerging Cross-Sectional Technologies | 49 | Expired |
| US8927513B2 | 5′ phosphate mimics | Chemistry; Metallurgy | 45 | Active |
| US8546143B2 | Compositions and methods for inhibiting expression of a target gene | Chemistry; Metallurgy | 44 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.